Adaptimmune Therapeutics (NASDAQ:ADAP - Free Report) had its price target reduced by Guggenheim from $4.00 to $3.00 in a research note released on Friday,Benzinga reports. They currently have a buy rating on the biotechnology company's stock.
Other equities analysts have also issued reports about the stock. StockNews.com lowered shares of Adaptimmune Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Thursday. HC Wainwright decreased their target price on shares of Adaptimmune Therapeutics from $4.00 to $3.50 and set a "buy" rating for the company in a research report on Thursday. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Adaptimmune Therapeutics has an average rating of "Buy" and an average price target of $3.16.
View Our Latest Stock Analysis on Adaptimmune Therapeutics
Adaptimmune Therapeutics Price Performance
Shares of NASDAQ:ADAP remained flat at $0.59 during trading on Friday. The stock had a trading volume of 5,185,940 shares, compared to its average volume of 1,705,188. The company has a quick ratio of 3.09, a current ratio of 3.09 and a debt-to-equity ratio of 0.26. Adaptimmune Therapeutics has a 1 year low of $0.42 and a 1 year high of $2.05. The firm has a market capitalization of $150.02 million, a PE ratio of -2.67 and a beta of 2.26. The business's 50-day moving average price is $0.88 and its 200-day moving average price is $1.03.
Institutional Trading of Adaptimmune Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Fullcircle Wealth LLC purchased a new stake in shares of Adaptimmune Therapeutics during the 3rd quarter worth about $33,000. Vontobel Holding Ltd. raised its holdings in Adaptimmune Therapeutics by 230.8% in the 3rd quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company's stock worth $41,000 after purchasing an additional 30,000 shares during the period. GSA Capital Partners LLP purchased a new position in Adaptimmune Therapeutics during the third quarter worth approximately $95,000. Boulder Hill Capital Management LP acquired a new stake in Adaptimmune Therapeutics in the first quarter valued at approximately $143,000. Finally, Jane Street Group LLC grew its holdings in Adaptimmune Therapeutics by 130.4% in the third quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company's stock valued at $166,000 after purchasing an additional 98,581 shares during the period. Institutional investors and hedge funds own 31.37% of the company's stock.
Adaptimmune Therapeutics Company Profile
(
Get Free Report)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
Featured Stories
Before you consider Adaptimmune Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptimmune Therapeutics wasn't on the list.
While Adaptimmune Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
